The independent source for health policy research, polling, and news.
1,121-1,140 of 1,316 results
The FDA granted approval for Spinraza in late December for use on children and adults with spinal muscular atrophy. Insurance coverage is mostly focused on infants and children.
The high cost of Spinraza, a new and promising treatment for spinal muscular atrophy, highlights how the cost-benefit analysis insurers use to make drug coverage decisions plays out in human terms.
Embattled opioid seller Mallinckrodt is one of many pharmaceutical companies boosting political contributions and lobbying on Capitol Hill.
The controversial 340B drug discount program for hospitals came under fire at a congressional hearing.
A little-noticed provision in President Donald Trump’s executive order on drug prices may offer a clue to why Big Pharma hasn’t opposed a bill that could bleed their balance sheets of millions of patients.
Report by CDC researchers finds a steady fall in opioid use in recent years, but the rates are still three times higher than in 1999.
Gabapentin, prescribed for epilepsy and nerve damage, is touted by federal health officials as an alternative to opioids for patients. But some are now abusing the drug.
Among hurdles: Older adults may have multiple illnesses that could complicate research or they might be unable to manage the commute.
As we get older, it helps to tickle the noggin with trivia. Here's a pop quiz to see what you have learned as a regular reader of Kaiser Health News.
A study finds that nearly 19 percent of people with mental illnesses use prescription drugs, while only 5 percent of other people do.
Experts say the loopholes would allow states to bypass some protections for people with preexisting conditions.
Documents examined by Kaiser Health News shed light on the workings of the Trump administration's “Drug Pricing and Innovation Working Group."
This year’s American Diabetes Association scientific meeting came with a hefty price — a policy of no photography and limits on social media. That did not go over well on Twitter.
Due to poor doctor-patient communication, most people with advanced cancer don’t know enough about their disease to make vital decisions.
One insurer is turning the tables on drugmakers with what may be a new job category: a sales force for cost-effective medicine.
With the cost of medications up 300 percent in the past decade, supporters see this as a first step to rein in prices.
A 22-year old man from Orange County, Calif., alleges in a lawsuit that his health insurer stopped paying for a crucial — and expensive — immunotherapy drug, leading him to become seriously ill. Treatments for patients with similar conditions are increasingly denied or interrupted, experts and patient advocates say.
One in 9 Medicare enrollees have COPD and many of them can’t afford the inhalers that keep them out of the emergency room.
A new JAMA study examines how drug rebates can direct money to middlemen and force Medicare patients to cough up more money.
A new law gives Medicaid regulators power to threaten drugmakers with cost-effectiveness scrutiny unless they grant additional rebates.
© 2026 KFF